Clinical implications of cardiac I-meta-iodobenzylguanidine scintigraphy and cardiac natriuretic peptides in patients with heart disease

Nuclear Medicine Communications

Volumn 23, Issue 8, 2002, Pages 795-801

  Ebina, T ^a   Takahashi, N ^a   Mitani, I ^a   Sumita, S ^a   Ishigami, T ^a   Ashino, K ^a   Minamisawa, K ^a   Kuji, N ^a   Ochiai, H ^a   Ishikawa, Y ^a   Oka, T ^a   Inoue, T ^a   Matsubara, S ^a   Umemura, S ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Heart disease; Meta iodobenzylguanidine (MIBG); Natriuretic peptide

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; (3 IODOBENZYL)GUANIDINE I 123; CHOLESTEROL; TRIACYLGLYCEROL;

ANGINA PECTORIS; ARTICLE; BLOOD; CARDIOMYOPATHY; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HEART DISEASE; HEART INFARCTION; HUMAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTION AND FORECASTING; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STATISTICS; VALVULAR HEART DISEASE; ADULT; CHOLESTEROL BLOOD LEVEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SCINTISCANNING; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PROGNOSIS; STATISTICAL MODEL; SURVIVAL; SYMPATHETIC TONE; TRIACYLGLYCEROL BLOOD LEVEL;

3-IODOBENZYLGUANIDINE; ANGINA PECTORIS; ATRIAL NATRIURETIC FACTOR; CARDIOMYOPATHIES; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HEART VALVE DISEASES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS; COMPARATIVE STUDY; HUMAN; MIDDLE AGE; MYOCARDIAL DISEASES;

EID: 0035991813     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200208000-00014     Document Type: Article

References (27)

1. Cohn JN, Levine BT, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 331: 819-823.
2. Chidsey CA, Braunwald E, Morrow AG. Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med 1965; 39: 442-451.
3. Kline RC, Swanson DP, Wieland DM, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med 1981; 22: 129-142.
4. Glowniak JV, Frederick ET, Lori LG, Robert TP, Manuel CL-S, William RW. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J Nucl Med 1989; 30: 1182-1191.
5. Henderson EB, Kahn JK, Corbett JR, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988; 78: 1192-1199.
6. Schofer J, Spielmann R, Schuchert A, Weber K, Schlüter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988; 12: 1252-1258.
7. Merlet P, Valette H, Dubois-Randé J-L, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33: 471-477.
8. Merlet P, Benvenuti C, Moyse D, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999; 40: 917-923.
9. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339: 321-328.
10. Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989; 13: 1534-1539.
11. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730-1736.
12. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-516.
13. Stanek B, Frey B, Hülsmann M, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001; 38: 436-442.
14. Omland T, Aakvaag A, Boarjee VVS, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996; 93: 1963-1969.
15. Imamura Y, Ando H, Mitsuoka W, et al. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol 1995; 26: 1594-1599.
16. Somsen GA, van Vlies B, de Milliano PAR, et al. Increased myocardial [123I]-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure. Heart 1996; 76: 218-222.
17. Nakata T, Miyamoto K, Doi A, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 1998; 5: 579-590.
18. Suwa M, Otake Y, Moriguchi Y, et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to β-blocker therapy in patients with dilated cardiomyopathy. Am Heart J 1997; 133: 353-358.
19. Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduced cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1997; 38: 1085-1089.
20. Toyama T, Aihara Y, Iwasaki T, et al. Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after β-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med 1999; 40: 217-223.
21. 123I-MIBG scintigraphic study. J Nucl Med 2000; 41: 845-851.
22. Francis GS, Benedict C, Johnson DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724-1736.
23. Rouleau J-L, Packer M, Moyé L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994; 24: 583-591.
24. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-1453.
25. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825-832.
26. Hiroe M, Hirata Y, Fujita N, et al. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. Am J Cardiol 1991; 68: 1114-1115.
27. Wei C-M, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994; 89: 1580-1586.